In Episode 3 of ET Titan Talks, Deepak Ajwani, Editor, The Economic Times Digital, speaks with Dr Ram Charan, management guru ...

It's hard to find quality that endures from beginning to end, but that's exactly what you'll get in these action-packed first ...

Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish ...

Computers have long ⁠been key ​to the $88 trln ​industry. Now artificial intelligence threatens to remove people ​from ...

Xbox brings in Microsoft CoreAI executives to reshape its platform team, with new VPs for engineering, design, and growth ...

A major owner of Rapport Therapeutics reported selling 426,005 shares for a total value of approximately $17.18 million on April 17, 2026. The transaction accounted for 5.3% of Third Rock Ventures V, ...

Viridian Therapeutics, Inc. , a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported ...

This isn’t science fiction. It’s emerging biology — and it might be the key to slowing, or even halting, the aging process ...

The AUM model is a straight percentage fee charged annually on the total value of the assets the advisor manages for you. It is the usual model used by wealth management professionals. AUM fees ...

The board problem is now hiding in plain sight: Strategy is not just being challenged more often. Its half-life is collapsing ...

Financial advisors and their clients are largely on the same page about what keeps them up at night – and it's not a lack of market optimism, according to a new survey from InspereX. The Spring 2026 ...